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Wnt signaling plays a critical role in embryonic devel-
opment, and genetic aberrations in this network have
been broadly implicated in colorectal cancer.We find
that the Wnt receptor Frizzled2 (Fzd2) and its ligands
Wnt5a/b are elevated in metastatic liver, lung, colon,
and breast cancer cell lines and in high-grade tumors
and that their expression correlates with markers of
epithelial-mesenchymal transition (EMT). Pharmaco-
logic and genetic perturbations reveal that Fzd2
drives EMT and cell migration through a previously
unrecognized, noncanonical pathway that includes
Fyn and Stat3. A gene signature regulated by this
pathway predicts metastasis and overall survival in
patients. We have developed an antibody to Fzd2
that reduces cell migration and invasion and inhibits
tumor growth and metastasis in xenografts. We
propose that targeting this pathway could provide
benefit for patients with tumors expressing high
levels of Fzd2 and Wnt5a/b.INTRODUCTION
The epithelial-mesenchymal transition (EMT) is a reversible pro-
cess in which epithelial cells adopt mesenchymal properties
by altering their morphology, cellular architecture, adhesion,
and migratory capacity (Lee et al., 2006). EMT was originally
defined in the context of metazoan developmental stages,
including heart morphogenesis and mesoderm and neural crest
formation (Savagner, 2010). A similar process (also called EMT)
is activated during the development of organ fibrosis and wound
healing (Thiery et al., 2009). During tumor progression, EMT
allows benign tumor cells to infiltrate surrounding tissue and
metastasize to distant sites. More recently, several studies
have postulated a link between EMT and stem cell characteris-
tics (Gupta et al., 2009), as well as drug resistance, reinforcing
the idea that EMT is closely linked to morphogenesis and tumor
progression (Thiery et al., 2009).
Induction of EMT involves downstream transcription factors,
such as Snail and Twist, as well as cytokines, such as MMP2
and MMP9. Several growth factors, including TGFb, Wnt, EGF,844 Cell 159, 844–856, November 6, 2014 ª2014 Elsevier Inc.FGF, and HGF, have been shown to trigger EMT in both embry-
onic development and normal and transformed cell lines (Thiery
et al., 2009). However, mechanistic understanding of how
specific growth factors induce EMT is still lacking. Uncovering
the signaling pathways by which growth factors regulate EMT
could have broad biological significance and could potentially
guide the development of new therapies directed at cancer
metastasis.
In this paper, we study the role of Wnt signaling in the regu-
lation of EMT and cancer metastasis. Wnt family proteins are
growth factors that play critical roles in proliferation, migration,
and invasion. They bind to and activate one ormore of ten known
seven-transmembrane Fzd family receptors (Willert et al., 2003).
Defective Wnt signaling plays a critical role in the early stages of
colon cancer (Klaus and Birchmeier, 2008). For example, >90%
of all sporadic colon cancers feature aberrant Wnt signaling,
usually as a result of mutations in genes encoding adenomatous
polyposis coli (APC; 80%), b-catenin (CTNNB1; 10%), or Axin
(Giles et al., 2003). Many previous studies have uncovered acti-
vation of canonical Wnt/bcatenin signaling during EMT (Deka
et al., 2010; Gupta et al., 2010; Wu et al., 2012). These studies
show that, during the EMT process, there is an increase in nu-
clear b-catenin (likely due to loss of membranous E-cadherin)
and transcriptional activity of T cell factor (TCF). However, it is
not clear whether EMT is directly caused by ligand-driven canon-
ical signaling. Upregulation of noncanonical Wnt ligand (Wnt5a)
and activation of noncanonical Wnt components, including
PKC and JNK, have also been observed during EMT (Dissa-
nayake et al., 2007; Jordan et al., 2013; Scheel et al., 2011). How-
ever, a mechanistic understanding of how Wnt5a induces EMT
and whether it is canonical or noncanonical, or whether it is by
any previously identified pathway, is left unanswered by previous
investigations.
We systematically assessed Wnt and Fzd transcripts in a
variety of cancer cell lines and correlated their levels with epithe-
lial and mesenchymal markers. We found that the Wnt5a
and Wnt5b ligands, along with their cognate receptor Fzd2, are
generally overexpressed in cell lines derived from late-stage
mesenchymal-type hepatocellular carcinomas (HCC) and can-
cers of the breast, lung, and colon. Fzd2was also overexpressed
in late-stage clinical cases of HCC and lung cancer, and over-
expression was correlated with poor patient survival. Reducing
receptor expression by RNAi or blocking receptor activity with
anti-Fzd2 antibodies reduced Wnt5-mediated cell migration
BLiver (n=28)
Cav2
Snai2
Fn1
Mmp2
Ddr2
Cdh2
Twist1
Spp1
Dsp
Krt19
Cdh1
EpCam
Cldn3
Colon (n=62)
Wnt5b
Wnt5a
Cldn1
Cldn4
Cldn7
Breast (n=59)
Lung (n=186)
Cav2
Snai2
Fn1
Mmp2
Ddr2
Twist1
Spp1
Dsp
Krt19
Cdh1
EpCam
Cldn3
Wnt5b
Wnt5a
Cldn4
Cldn7
Fzd2
Cdh2
Snai2
Fn1
Mmp2
Ddr2
Twist1
Spp1
Dsp
Krt19
Cdh1
EpCam
Cldn3
Wnt5a
Wnt5b
Cldn4
Cldn7
Cldn1
Cav2
Snai2
Mmp2
Ddr2
Cdh2
Twist1
Spp1
Dsp
Krt19
Cdh1
EpCam
Cldn3
Wnt5b
Wnt5a
Cldn1
Cldn4
Cldn7
Fzd2
Fzd2
Fzd2
A D
E
C
Figure 1. Fzd2 and Its Cognate Ligands Wnt5a/b Are Overexpressed in Late-Stage Cancers, and Their Expression Correlates with
Mesenchymal Markers
(A) Heatmaps showing correlation of Fzd2 and its ligands Wnt5a/b with mesenchymal markers in 59 breast, 62 colon, 28 liver, and 186 lung cancer cell lines.
(B) Bar graph showing that Fzd2 mRNA expression is significantly increased in late stages (stages III and IV) of primary liver and lung cancers compared with
normal tissue (p < 0.05).
(C) Fzd2 regulates cell migration. Top, relative wound density (RWD) of Fzd2-shRNA- or control-shRNA- (sh-Ctl) expressing FOCUS and BT549 mesenchymal
cells. Bottom, RWDof Fzd2-expressing or control vector-expressing Huh7 andDld1 epithelial cells. RWD is ameasure of the spatial cell density in thewound area
relative to the spatial cell density outside of the wound area at every time point.
(D) Fzd2 signaling regulates EMT program. Representative images showing that expression of Fzd2 in Huh7 cells decreased levels of the epithelial markers
E-cadherin and Occludin and increased levels of the mesenchymal markers Foxc1 and Vimentin. Blue, nucleus stain.
(E) Volume plot of 75 EMT genes measured by qPCR in FOCUS cells expressing Ctl-shRNA or Fzd2-shRNA (left) or Huh7 cells expressing vector only or Fzd2
expression vector (right). A set of genes that were significantly downregulated (p < 0.05) upon knockdown of Fzd2 are shown in red, whereas significantly
upregulated (p < 0.05) genes are shown in green.
Error bars indicate SEM. See also Figures S1 and S2.in vitro and inhibited tumor growth and metastasis in a mouse
xenograft model. Further analysis of the pathway leading from
Fzd2 to migration revealed a role for several previously unrecog-
nized molecules, including Fyn, a Src family kinase, and Stat3,
a transcription factor. These data establish a noncanonical
Wnt pathway involving Fzd2 receptor, Fyn tyrosine kinase, and
the Stat3 transcriptional regulator as a driver of EMT in diverse
solid tumors; cell culture and murine experiments highlight
Fzd2 as a potential therapeutic target for late-stage and meta-
static cancer.RESULTS
Fzd2 Is Overexpressed in Poorly Differentiated,
Mesenchymal-type Cancers
To probe the roles of Wnt and Fzd proteins in EMT, we assessed
gene expression levels for 16 Wnt ligands and 10 Fzd receptors
in 27 HCC cell lines (Figures 1A and S1 available online) (Barre-
tina et al., 2012). Based on morphology and expression of bio-
markers such as E-cadherin and vimentin, these lines span a
range of phenotypes from well to moderately differentiated andCell 159, 844–856, November 6, 2014 ª2014 Elsevier Inc. 845
epithelial like to poorly differentiated and mesenchymal like
(Fuchs et al., 2008). A statistical information-gain approach re-
vealed that the expression level of Fzd2 is the best single-gene
discriminator of poorly versus well-differentiated HCC cell lines
in our collection (Figure S1). In addition, ligands for Fzd2 receptor
(Wnt5a andWnt5b) were more highly expressed in poorly differ-
entiated cell lines than in well-differentiated lines (Figure S1).
Expression of Fzd2 and its cognate ligands (Wnt5a and Wnt5b)
correlated positively with each other and with markers of mesen-
chymal cells, such as vimentin (VIM), N-cadherin (CDH2), and
fibronectin (FN1), in panels of breast (n = 59), colon (n = 62), liver
(n = 28), and lung (n = 186) cancer cell lines (Figures 1A and S1).
Conversely, expression of Fzd2 and Wnt5a/Wnt5b correlated
negatively with markers of epithelial cell differentiation, such as
Epcam (Epcam), E-cadherin (CDH1), and keratin (KRT18; Fig-
ure 1A). In a panel of 48 tissue samples from patients with either
liver or lung cancers, we found that Fzd2 was significantly over-
expressed in late-stage cancer (stages III and IV) relative to
normal tissue and early-stage cancer (stages I and II) (HCC,
p = 0.0051; lung, p = 0.032, Figure 1B). As in cell lines, levels
of Fzd2 correlated negatively with the degree of tissue differen-
tiation—moderately and poorly differentiated tumors exhibited
higher levels of Fzd2 compared to well-differentiated tumor
types (Figure S1). We therefore conclude that Wnt5a, Wnt5b,
and Fzd2 are statistically significant markers of poorly differen-
tiated, mesenchymal-type cancer in diverse cell lines and in
human tumor tissue samples.
Fzd2 Regulates Epithelial-Mesenchymal Transition
and Cellular Migration
To determine whether Fzd2 signaling is required for cell growth
or migration and whether Wnt5-Fzd2 signaling regulates EMT,
we depleted or overexpressed Fzd2 in poorly differentiated or
well-differentiated cell lines, respectively. No differences were
observed in cell viability between control and RNAi-treated cells
(Figure S1). However, whenwe assayed for cell migration using a
real-time wound-healing assay, a significant reduction in closure
time was observed in Fzd2-depleted cells as compared to con-
trol FOCUS (liver) and BT549 (breast) cells (p < 0.05; Figure 1C).
Knockdown of Fzd2 also caused a decrease in cell invasion (p <
0.05; Figure S1). Cell lines that are poorly differentiated and
express high levels of Wnt5 and Fzd2 (SNU449, SNU475, and
FOCUS) migrated faster than well-differentiated lines in which
ligand and receptor levels are low (HepG2 and Huh7) (Figure S1);
when Fzd2 was overexpressed in cells with low or undetectable
levels of endogenous Fzd2 (Huh7, liver and Dld1, colon), we
observed a significant increase in cell migration compared to
vector-only control (p < 0.05; Figure 1C). Overall, these data
suggest that Fzd2 plays a causal role in cell motility.
Because Fzd2 levels correlate with mesenchymal markers
in many cancer cell lines (Figure 1A), we hypothesized that
Wnt5-Fzd2 signaling might drive EMT. To test this, the levels of
75 EMT-associated genes were assessed in Huh7 cells over-
expressing Fzd2 (Huh7 parental cells have low levels of Fzd2)
or in FOCUS cells (which are in high in Fzd2) depleted of Fzd2
by RNAi (Figures 1D and 1E). Overexpression of Fzd2 in Huh7
cells caused a significant decrease in the expression of epithelial
markers such as Cdh1 (E-cadherin), Ocln (Occludin), and Keratin846 Cell 159, 844–856, November 6, 2014 ª2014 Elsevier Inc.(Krt19), whereas expression of mesenchymal markers such as
Mmp2, Mmp9, andMsnwas elevated (Figures 1D and 1E). Over-
expression of Fzd2 also led to increased mRNA levels of Wnt5a/
b, suggesting activation of an autocrine positive feedback loop
(Figure 1E). Conversely, in FOCUS cells depleted of Fzd2,
mRNA levels for mesenchymal markers were reduced, including
Spp1, Mmp2, Snai2 (Slug), and Mmp9, and expression of
epithelial markers was elevated, including Cdh1, Ocln, and
Gsc (Figure 1E). Similar results were obtained at the protein
level based on reverse-phase protein arrays for E-cadherin,
Occludin, MMP9, and Slug (Figure S1). Taken together, these
data suggest that Fzd2 signaling drives expression of genes
associated with EMT.
Fzd2-Mediated Cell Migration Is Not Dependent on
Canonical Wnt Signaling or Previously Described
Noncanonical Pathways
Previous studies have shown that Fzd2 can activate both b-cat-
enin-dependent (canonical) and b-catenin-independent (nonca-
nonical) signaling (Grumolato et al., 2010). Canonical signaling
involves the transcription factor TCF, whose activity can be
monitored using well-characterized TOPglow and FOPglow
reporter constructs. Exposing late-stage HCC cell lines that
overexpress Wnt5/Fzd2 (FOCUS, SNU449, and SNU475) to
Wnt3a did not activate TCF reporter activity, but Wnt3a did acti-
vate TCF in well-differentiated HCC lines that express low levels
of Wnt5/Fzd2 (HepG2 and Huh7; Figure S2). Thus, a switch
appears to occur between canonical and noncanonical Wnt
signaling at some stage in tumor progression. Depending on
cellular context, noncanonical signaling has been shown to
involve a diverse set of signaling molecules, including Rho,
Rac, Rock, PI3K, CK1, PKA, PKC, JNK, mTOR, and Dvl (Fig-
ure S2). Because many of the liver cell lines in our collection
proved difficult to transfect with RNAi, a pharmacological
approach was used to determine whether Fzd2-mediated cell
migration depends on these or other factors. Treating FOCUS
cells with inhibitors of GSK3b (TDZD-8), Axin (IWR-1), b-cate-
nin-TCF (PNU074654), b-catenin stabilization (XAV939), or any
of the ten mediators of noncanonical Wnt signaling listed above
did not significantly affect Fzd2-mediated cell migration (p <
0.05) (Figure S2). Overall, these data suggest that Fzd2-medi-
ated promigratory signaling is not dependent on the b-catenin/
TCF pathway but instead involves a previously uncharacterized,
noncanonical pathway.
Discovery of a Noncanonical Signaling Pathway
Downstream of Fzd2
To identify alternative pathways involved in Wnt5-Fzd2-medi-
ated EMT and cell migration, we evaluated the basal activities
of 45 reporters for different transcription factors involved in
signaling pathways that have been implicated in oncogenesis
in FOCUS cells expressing either Fzd2-specific shRNA (FOCUS-
shFzd2) or control-shRNAs (FOCUS-shCtl) (Figure 2A and
Table S1). A 10-fold reduction was observed in the activity of
the Stat3 transcriptional reporter (p < 0.001) when Fzd2 was
depleted and Elk-1- and Sp1-specific reporters were also
affected to a lesser degree (Figure 2A). Exposing cells to an in-
hibitor of Wnt secretion (C59) decreased Stat3 transcriptional
Ctl-shRNA+Wnt5a
Fzd2-shRNA+Wnt5a
A
R
el
at
iv
e 
P
ho
sp
ho
ry
la
tio
n 1.2
0.0
0.2
0.6
0.8
1.0
0.4
Ctl-shRNA Fzd2-shRNA
pStat3 pMek pErk pAkt
B
10
8
4
2
6
0
R
el
at
iv
e 
Lu
ci
fe
ra
se
 A
ct
iv
ity
(fi
re
fly
/re
ni
lla
)
*
* **
45 Transcriptional Reporters
*
Stat3
Nfκb
Elk1
Sp1
Nrf1/2
Po
s
Ne
g
IP:
Lysates
Fz
d2
IgG St
at3 IgG
Fzd2
Stat3
Stat3
Fzd2
Co-IP (Focus cells)
1.2
0.9
0.6
0.3
0.0
M
FI
0 16 64 12
8
19
2
25
6
pStat3 pErk
pAktpMek1
D Wnt5a stimulation
Ctl-shRNA
Fzd2-shRNA
1.2
0.9
0.6
0.3
0.0
M
FI
0 16 64 12
8
19
2
25
6
Time (min)
0 16 64 12
8
19
2
25
6
Time (min)
0 16 64 12
8
19
2
25
6
F
Time (min) Time (min)
Oncogenic signaling pathway activation
E
Log Inhibitor [μM]
2-6 -5 -4 -3 -2 -1 0 1
R
el
at
iv
e 
W
ou
nd
 D
en
si
ty
 (%
) 100
80
60
20
0
40
MEKiStat3i
FOCUS
SNU449
3.8 μM>50 μM
5.4 μM>50 μM
EC50
Cell
G
Cd
h1
Bm
p2
Ts
pa
n1
3
Oc
ln
Sp
p1
Tg
b2
Mm
p2
Mm
p3
Mm
p9
1
0
-1
-2
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on
 (l
og
10
)
sh-Ctl
sh-Stat3
EMT signature
Epithelial Mesenchymal
S
ta
t3
 tr
an
sc
rip
tio
n 
ac
tiv
ty
0
50
Huh7 +Fzd2
100
150
200
PB
S
W
nt5
a
0R
el
at
iv
e 
W
ou
nd
 D
en
si
ty
 (%
)
100
80
60
20
0
40
10 20 30 40 50 60
sh-Ctl
sh-Stat3
Time (h)
Cell migration
Stat3 knockdown
FOCUS
(liver) 
0 20 40 60 80 100
Time (h)
Dld1 
(colon)
Vector
 Stat3C
Stat3 overexpression
0 6 12 18 24
Fzd2 overexpression
+ Stat3 inhibitor
Vector
Fzd2
Fzd2 +Stat3i 
(1 μΜ)
Time (h)
Fzd2 +Stat3i 
(12 μΜ)
Fzd2 +Stat3i 
(5 μΜ)
C
H
Huh7
(liver)
100
80
60
20
0
40
Figure 2. Stat3 Is a Key Mediator of Fzd2-Mediated Downstream Signaling, EMT Program, and Cellular Migration
(A) Comparison of 45 different signal transduction pathways in FOCUS cells transfected with Fzd2 or control shRNA using a 45-transcription factor reporter array.
Signaling pathways that showed significant change in Fzd2 knockdown samples are indicated. Neg and Pos denote negative and positive luciferase controls.
(B) Bar graph showing increase in transcription activity of Stat3 upon Wnt5a stimulation in Fzd2-expressing Huh7 cells.
(C) Bar graph showing decrease in phosphorylation of Stat3, Erk1, andMek1 upon Fzd2 knockdown in FOCUS cells. The relative phosphorylation of Akt (Ser473)
is unchanged in Fzd2-shRNA-expressing cells.
(D) Wnt5a stimulation increases phosphorylation of Stat3, Erk, and Mek in a Fzd2-dependent manner.
(E) Treatment with Stat3 inhibitor reduces FOCUS cell migration. Dose response curves showing EC50 (50% reduction in cell migration compared with DMSO
control) in FOCUS and SNU449 liver cancer cell lines treated with Stat3 or Mek inhibitors.
(F) Western blots showing that Fzd2 and Stat3 associate in a coimmunoprecipitation assay. Lysates immunoblotted with anti-Stat3 and anti-Fzd2 are also shown.
(G) Perturbing Stat3 expression reverses EMT in FOCUS cells. Bar graph shows expression of epithelial and mesenchymal marker genes in FOCUS cells with
knockdown of Stat3.
(H) Stat3 activity regulates cell migration. Knocking down expression of Stat3 decreases Fzd2-mediated cell migration in FOCUS cells (left), whereas expression
of constitutively active Stat3 (Stat3C) increased migration of Dld1 epithelial cells (middle). Treatment with Stattic (Stat3 inhibitor) decreased migration of Fzd2-
overexpressing Huh7 cells (right) in a dose-dependent manner.
Error bars indicate SEM. See also Figures S3, S4, and S5 and Table S1.
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activity in FOCUS cells 2- to 4-fold, whereas overexpressing
Fzd2 in Huh7 cells increased Stat3 activity 2-fold (Figure 2B).
Depletion of Fzd2 in other poorly differentiated, high Wnt5-
Fzd2-expressing cell lines, including SNU449 (liver) and BT-
570 (breast), decreased Stat3 transcriptional activity, whereas
Elk-1 activity was not changed (Figure S3). Further, depletion
of Fzd2 in FOCUS cells also decreased expression of several
Stat3 target genes, including IL2RG, STAM, PLAU, SerpinE1,
and MMP3 (Figure S3). Stat3 activity is typically induced by
receptor tyrosine kinases (RTKs) or by the interleukin-6 (IL-6)-
Janus kinases (JAK) pathway, whereas Elk-1 is activated by
the MAPK pathway (Davis et al., 2000). Consistent with these
established mechanisms, phosphorylation of Stat3 (pSer727),
Mek1(pSer217/pSer221), and Erk1 (pThr202/Tyr204) was reduced
by Fzd2 depletion, but Akt phosphorylation (pSer473) and the
transcriptional activity of FOXO (which lies downstream of the
Akt pathway) was unaffected (Figures 2C and S3). When cells
were exposed to exogenousWnt5a, Fzd2-dependent phosphor-
ylation of Stat3, Mek1/2, and Erk1/2 (but not Akt) was observed
(Figure 2D).
Small-molecule inhibitors were used to investigate whether
the Stat3 and/or MAPK pathways, both of which have docu-
mented roles in cell migration (Tarcic et al., 2012; Teng et al.,
2009), play a causal role in Fzd2-mediated migration in liver,
lung, and breast cancer cell lines (Figures 2E and S3). Despite
its low potency, the Stat3 inhibitor Stattic (IC50 5 mM) (Schust
et al., 2006) decreased migration in cell lines expressing high
levels of Fzd2; inhibition was observed in the low micromolar
range. In contrast, even the relatively potent MEK inhibitor
U0126 (IC50 70 nM) (Duncia et al., 1998) had no effect on cell
migration in six cell lines tested (Figures 2E and S3). Although
it is plausible that Ras-ERK signaling can contribute to EMT or
other aspects of tumor progression, we conclude that Stat3,
rather than MAPK/Elk-1, is more likely to play a causal role in
Fzd2-mediated cell migration.
Stat3 Interacts with Fzd2 and Plays a Critical Role
in Wnt5-Fzd2-Mediated EMT and Cell Migration
Stat3 is phosphorylated on Tyr705 or Ser727, two sites required for
maximal transcriptional activity in response to cytokines (Wen
et al., 1995). To determine which Stat3 phosphorylation sites
are involved in Wnt5-Fzd2 signaling, we overexpressed a wild-
type or a constitutively active mutant, Stat3-C (Takahashi and
Yamanaka, 2006). This resulted in 2-fold and 4-fold increases
in Stat3 transcriptional activity, respectively (Figure S3). Overex-
pression of Stat3-S727A (Wen and Darnell, 1997) also increased
transcription 2-fold in FOCUS cells, similar to wild-type Stat3. In
contrast, overexpression of Stat3-Y705F (Wen and Darnell,
1997) was indistinguishable from vector-only control. These
data suggest that Stat3-pTyr705 is involved in Fzd2-mediated
signaling. In addition, we found that endogenously ex-
pressed Fzd2 and Stat3 coimmunoprecipitated reciprocally in
four different cancer cell lines (FOCUS, BT549, Calu1, and
NCIH661) (Figures 2F and S3). A pull-down assay using a GST-
Stat3 fusion protein, however, failed to recover Fzd2 from
FOCUS cell lysates, suggesting that the interaction may be
indirect (Figure S3). Stat3 depletion reduced the expression of
mesenchymal markers such as Spp1, Mmp2, Snai2 (Slug), and848 Cell 159, 844–856, November 6, 2014 ª2014 Elsevier Inc.Mmp9 and enhanced expression of epithelial markers such as
Cdh1 and Ocln (Figure 2G), whereas overexpression of constitu-
tively active mutant (Stat3-C) in Huh7 epithelial cells decreased
expression of epithelial markers such as Cdh1, Krt19, and Ocln
and increased levels of Vimentin (Figure S3). Similar changes
were observed in cells treated with a pharmacological inhibitor
of Stat3 and were dose- and time-dependent (Figure S3). As
further confirmation, knocking down Stat3 by RNAi impaired
wound closure in FOCUS cells, whereas overexpression of
constitutively active Stat3 increased cell migration in Dld1 colo-
rectal cancer cells, which have low levels of Fzd2 (Figure 2H).
Finally, pharmacological inhibition of Stat3 in Fzd2-expressing
Huh7 cells abolished cell migration in a dose-dependent manner
(Figure 2H). We conclude that Fzd2-dependent EMT and cell
migration involves Stat3 activation and that this likely involves
phosphorylation of Stat3 on Tyr705. Moreover, Fzd2 and Stat3
physically associate, most likely in a complex involving addi-
tional proteins.
Fzd2 Mediates Stat3 Activation and Cell Migration
Independent of Janus Kinases
Although Stat3 is phosphorylated on Tyr705 in a Wnt5–Fzd2-
dependent manner (Figure S3), Fzd2 is a member of the G-pro-
tein-coupled family of receptors and therefore lacks tyrosine
kinase activity. Treating FOCUS cells with any of three well-char-
acterized inhibitors of abg-trimeric G proteins (pertussis toxin,
Gallein, and Suramin) (Freissmuth et al., 1996; Katada, 2012)
had no effect on cell migration or Stat3 reporter activity (Fig-
ure S4), suggesting that activation of a heterotrimeric G protein
is not involved. We therefore searched for a kinase involved in
Fzd2-mediated phosphorylation of Stat3. JAKs phosphorylate
and activate Stat3 in response to cytokines (O’Shea et al.,
2002), and Stat3 activation by IL-6 in FOCUS or SNU449 (by
2- to 4-fold ; Figure S4) was blocked by ruxolitinib, a JAK1/2 in-
hibitor (Harrison et al., 2012), or tofacitinib, a pan-JAK inhibitor
(Paul and Roblin, 2012; EC50 < 1 nM; Figure S4). However,
JAK inhibition had little or no effect on Wnt5a-induced Stat3
transcription in either FOCUS or SNU449 cells except at drug
concentrations so high that selectivity is lost (EC50 > 15 mM; Fig-
ure S4). These data show that Janus kinases are required for
IL-6-, but not Wnt5a–Fzd2-mediated activation of Stat3.
To determine whether Fzd2 cross-activates an RTK that sub-
sequently phosphorylates Stat3, we used antibody microarrays
to monitor the tyrosine phosphorylation states of 40 RTKs and
12 downstream signaling kinases in FOCUS cells expressing
either Fzd2-specific or control shRNA (Figure S5). Previously
established differences in the phosphorylation levels of Stat3
and Akt (Figures 2C and 2D) were used as positive and negative
controls, respectively. No significant differences were observed
for 38 of 40RTKs examined, including ROR1, ROR2, andRYK, all
three of which have been shown to interact with Fzd2 andWnt5a
(Li et al., 2008; Lin et al., 2010) (Figure S5). Tyrosine phosphory-
lation of EGFR and c-Met, however, was reduced >2-fold (p <
0.05) in FOCUS-shFzd2 compared to FOCUS-shCtl cells. Quan-
titative western blotting confirmed these findings and revealed
that protein levels of these two receptors were reduced by
Fzd2 knockdown, as were transcript levels as determined by
qPCR (Figure S5). Despite these effects, stimulation with either
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Figure 3. Fyn Kinase Is a Critical Regulator of Fzd2-Mediated Stat3 Activity
(A) Identification of informative kinases in Fzd2-mediated cell migration using kinome regularization. Plot shows LOOCV error using elastic net regularization fit.
The error bars represent cross-validation error plus 1 SD. The kinases identified at absolute minima (blue dashed line) were termed the most informative kinases.
(B) Evolution of regression coefficients. Plot showing regression coefficients for Fyn kinase against value of elastic-net penalty a. Nonzero regression coefficients
for kinases picked at a > 0.5 (gray region) are considered significantly informative.
(C) Src family kinase inhibitor reduces Fzd2-mediated cellular migration. Relative wound density of cancer cells treated with varying concentration of Dasatinib
was monitored for 96 hr. Dose-response curves of Dasatinib treatment in seven cancer cell lines and respective EC50 are shown.
(D) Knockdown of Fzd2 expression reduces phosphorylation of SFKs in FOCUS cells, whereas overexpression of Fzd2 increases Src phosphorylation in Huh7
cells.
(E) Fyn kinase phosphorylates Stat3. Western blots showing phosphorylation of Stat3 upon knockdown of Fyn in FOCUS cells.
(F) Wnt5-Fzd2-dependent Stat3 transcription activity can be rescued by overexpression of active Src in Fzd2 or Fyn knockdown cells.
(G) Overexpression of active SFK (SrcY527F) in Huh7 cells increased transcriptional activity of Stat3.
Error bars indicate SEM. See also Figure S6.EGF or HGF or inhibition with EGFR family kinase inhibitors
(Lapatinib, Erlotinib, and Gefitinib) or c-Met kinase inhibitors
(SU11274 and Crizotinib) had no observable effect on either
cell migration or Stat3 activity at reasonable drug concentrations
(<10 mM, Figure S5). We conclude that Fzd2 may cross-regulate
EGFR and c-Met, but neither receptor plays a causal role in
Wnt5-mediated cell migration.
Kinome Regularization Identifies Fyn Kinase as a Key
Mediator of Fzd2 Signaling and Cellular Migration
Having eliminated two obvious candidates for the Stat3 kinase,
we used a recently established unbiased method of target de-
convolution, kinome regularization (KR), which exploits the poly-
pharmacology of kinase inhibitors (Gujral et al., 2014). In this
method, LASSO, a multivariate regression technique, was used
to regress a single target variable (quantified cell migration)
against a set of second variables (the activities of individual
kinases assayed in vitro at 500 nM) while imposing a penalty
that eliminates poorly correlated variables (kinases with insig-nificant contributions). Leave-one-out cross-validation using
least-mean-square error implicated a panel of 16 kinases in
phosphorylating Stat3 in FOCUS cells (Figure 3A). Of these, eight
were tyrosine kinases, and Fyn in particular was identified as an
‘‘informative kinase’’ in both FOCUS and Hs578t cells (Figures
3B and S6). The pan-specific Src family kinase (SFK) inhibitor
Dasatinib reduced cell migration not only in FOCUS cells but
also in other high Fzd2-expressing cell lines, including HCC
(SNU449 and SNU475), breast (BT-549 and Hs578t), and lung
(Calu-1 andNCI-H661) with EC50 values of 3–100 nM (Figure 3C).
SFK phosphorylation was reduced 3-fold in FOCUS-shFzd2
cells as compared to FOCUS-shCtl cells, whereas it was
increased 3-fold in Fzd2-expressing Huh7 cells compared to
vector-only-expressing Huh7 epithelial cells, as assayed using
an antibody that recognizes a conserved site of tyrosine phos-
phorylation present on all SFKs and corresponding to Tyr416 in
Src (Figures 3D and S6). Consistently, phosphorylation of Fyn-
Tyr420 was also reduced by 2-fold in FOCUS-shFzd2 cells as
compared to FOCUS-shCtl cells (Figure S6). Knockdown ofCell 159, 844–856, November 6, 2014 ª2014 Elsevier Inc. 849
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Figure 4. Fyn Regulates Fzd2-Mediated EMT Program and Cellular Migration
(A and B) (A) Perturbing Fzd2-dependent Fyn activity reverses EMT. Plots showing mRNA expression of selected EMT genes measured by qPCR in FOCUS cells
expressing shRNA against Fyn or (B) Huh7 cells expressing active Src (Src Y527F).
(C) Representative images showing expression of active Src in Huh7 cells decreased levels of epithelial markers, E-cadherin, and Occludin and increased levels
of mesenchymal markers, Foxc1, Slug, and Vimentin. Blue nucleus stain. Scale bar, 100 pixels.
(D) Heat map showing effect of Fyn inhibitor (Dasatinib) on expression of EMT-associated genes.
(E and F) Fyn-shRNA showed significant decrease in Fzd2-mediated cell migration in FOCUS cells, whereas expression of SrcY527F increases cell migration in
Huh7 cells. Treatment with Stattic (Stat3 inhibitor) decreased migration of Huh7 cells expressing SrcY527F to the wild-type Huh7 levels.
Error bars indicate SEM. See also Figure S6.Fyn also inhibited Stat3-Tyr705 phosphorylation and transcrip-
tional activity, suggesting that Fyn kinase lies upstream of
Stat3 (Figures 3E and 3F). We note, however, that Stat3 activity
can also be induced >6-fold by overexpressing a constitutively
active form of Src (Src-Y527F) in FOCUS cells (Figure 3F) or
Huh7 cells (Figure 3G) or in FOCUS cells depleted of either
Fzd2 or Fyn, suggesting that SFK members may be functionally
redundant (Figure 3F).
Next, we assessed whether Fyn also plays a role in Fzd2-
mediated regulation of EMT. RNAi-mediated depletion of Fyn
in FOCUS cells reduced expression of the mesenchymal850 Cell 159, 844–856, November 6, 2014 ª2014 Elsevier Inc.markers Mmp2, Snai2, and Mmp9, whereas expression of
epithelial markers was elevated, including Cdh1, Bmp2, and
Tspan13 (as assayed at the mRNA level Figure 4A). Consis-
tently, expression of functionally redundant active SFK in
Huh7 epithelial cells decreased expression of epithelial markers
(Bmp2, Cdh1, and Krt19), whereas expression of mesenchymal
markers (Mmp2, Mmp9, Vim, Foxc1, Slug, Msn, and Tgfb1)
was significantly increased, suggesting that Fyn is a critical
regulator of EMT (Figures 4B and 4C). Similar results were ob-
tained in FOCUS cells treated with the Fyn inhibitor Dasatinib,
and changes in expression were dose- and time-dependent
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Figure 5. Fzd2 Is Tyrosine Phosphorylated and Is Directly Associated with the Fyn-SH2 Domain
(A) Schematics showing domain structures of Fyn-kinase and Fzd2 proteins. Fyn contains an SH3 domain, SH2 domain, and a kinase domain. Fzd2 is a seven
transmembrane domain-containing protein. Tyrosine residues in the first cytosolic loop (Y275) and in the C-terminal tail (Y552) are highlighted. Dvl-binding
sequence in the C-terminal domain of Fzd2 is also shown.
(B) Fzd2 is tyrosine phosphorylated in three HCC cell lines. Western blots showing tyrosine phosphorylation of Fzd2 detected by immunoblotting with anti-
phosphotyrosine antibody (pY100) in immunoprecipitates. Total protein levels of Fzd2 and b-actin in whole-cell lysates are also shown.
(C) Fzd2-pY552 binds directly to the SH2 domain of Fyn. A peptide array consisting of phosphorylated tyrosine 275 (pY275), pY552, nonphosphorylated tyrosine 275
(Y275), Y552 and a peptide containing proline-rich region from the first cytoplasmic loop of Fzd2 (P276) were incubated with purified SH2 domain of Fyn, SH3
domain of Fyn, and purified Stat3 of GST control proteins. Protein-peptide interaction was measured by probing arrays with anti-GST antibody. A plot of relative
fluorescence intensity measured on the array is shown.
(D) Western blots showing GST pull-down of Fzd2 and Stat3 using purified SH2 domain of Fyn. The pull-downs were subjected to western blotting and
immunoblotted with anti-Fzd2, Stat3, and GST antibodies. Total protein levels of Fzd2 and b-actin in whole-cell lysates are also shown.
(E) SH2 domain of Fyn is critical for Wnt5/Fzd2-mediated Stat3 transcriptional activity. Stat3 transcriptional activity was measured in FOCUS cells transfected
with the indicated constructs.
(F) A bar graph showing Fzd2 tyrosine phosphorylation in FOCUS cells treated with DMSO, Dasatinib (1 mM), or Staurosporine (100 nM) for 30 min. Fzd2
phosphorylation was detected by immunoblotting with anti-phosphotyrosine antibody (pY100) in Fzd2 immunoprecipitates. Data are the mean of at least two
independent samples, and error bars indicate SEM.
Error bars indicate SEM. See also Figure S6.(Figure 4D). Depleting Fyn reduced the ability of FOCUS cells
to migrate in a wound-healing assay (Figure 4E), whereas
expression of functionally redundant active SFK significantly
increased migration of Huh7 cells (p < 0.05) (Figure 4F).
Interestingly, inhibition of Stat3 activity in Huh7 cells express-
ing active Src decreased migration to wild-type Huh7 levels,
suggesting that Stat3 activity is important for SFK-mediated
cell migration (Figure 4F). We conclude that Fzd2 mediates
EMT and cell migration through Fyn-dependent activation of
Stat3.Fzd2 Is Tyrosine Phosphorylated and Directly
Associates with the SH2 Domain of Fyn
Fyn has the canonical architecture of a SFK, including an
N-terminal Src homology 3 (SH3) domain, followed by a Src
homology 2 (SH2) domain, a tyrosine kinase domain, and a short
C-terminal tail (Figure 5A) (Lenaerts et al., 2008). SH3 domains
bind to proline-rich motifs, whereas SH2 domains recognize
sites of tyrosine phosphorylation. Based on our current under-
standing of SFKs, the potential binding of Fyn to Fzd2 could
involve either its SH2 or SH3 domain. ImmunoprecipitationCell 159, 844–856, November 6, 2014 ª2014 Elsevier Inc. 851
of Fzd2 and immunoblotting with a pan-specific anti-phospho-
tyrosine antibody (pY100) revealed that Fzd2 is tyrosine phos-
phorylated in both FOCUS and SNU449 cells, as well as in
Wnt5a-induced Fzd2-expressing Huh7 cells (Figure 5B). Fzd2
contains two tyrosine residues that could potentially be phos-
phorylated: Tyr275 in the first cytoplasmic loop and Tyr552 in the
C-terminal tail. It also has a single proline-rich region in its
first cytoplasmic loop (the sequence 276PERP279). To determine
whether Fyn can bind either of the two phosphotyrosine sites, we
prepared a peptide array comprising phosphorylated and un-
phosphorylated 18-mer peptides containing Tyr275 or Tyr552 of
Fzd2, as well as a peptide containing the PERPmotif. We probed
the array with purified recombinant Fyn-SH2, Fyn-SH3, and
Stat3 (Figure 5C). Glutathione-S-transferase (GST) was used
as a negative control. The SH2 domain of Fyn bound the
pTyr552 peptide (Figure 5C), but neither the SH2 nor SH3
domains bound appreciably to the nonphosphorylated or
PXXP-containing peptides. Surface plasmon resonance mea-
surements showed that the SH2 domain of Fyn bound to the
pTyr552 peptide with an affinity (KD = 2.1 nM; Table S3) consis-
tent with previously reported SH2 domain-peptide interactions
by Src family members (Payne et al., 1993). None of the Fzd2-
derived peptides bound recombinant Stat3, which is consistent
with our hypothesis that the interaction between Fzd2 and Stat3
is indirect. To determine whether the SH2 domain of Fyn can
interact with full-length Fzd2 in a cellular environment, we per-
formed a pull-down experiment using recombinant GST-FynSH2
and lysates obtained from BT549, Calu-1, or FOCUS cell lines.
In all three cases, we detected Fzd2 binding to GST-FynSH2,
but not to GST alone (Figure 5D). We also detected Stat3 in
these pull-downs, which is consistent with formation of a multi-
protein complex that includes Fzd2, Fyn, Stat3, and possibly
other proteins as well.
To determine whether the SH2 domain of Fyn is required for
Stat3 activation by Fzd2, we generated an SH2 domain
mutant, Fyn-R176E, that is predicted to fold correctly but
have substantially lower affinity for tyrosine phosphorylated
target peptides (Mariotti et al., 2001). When overexpressed
in FOCUS cells, wild-type Fyn and constitutively active
Src-Y527F increased Stat3 activity 2- to 7-fold, respectively,
whereas overexpression of Fyn-R176E decreased Stat3 activ-
ity 2-fold, implying that Fyn-R176E has dominant-negative
activity (Figure 5E). These data suggest that the SH2 domain
of Fyn is involved in Wnt5-Fzd2-mediated Stat3 activation.
To determine whether Fyn is the kinase responsible for phos-
phorylation of Fzd2, we treated cells with sufficient Dasatinib
to block Fyn autophosphorylation at Tyr420 but did not observe
a detectable reduction in Fzd2 phosphorylation (Figures 5F
and S6). As a positive control, we confirmed that phosphory-
lation of Fzd2 was substantially decreased when cells were
treated with Staurosporine, a broad-spectrum kinase inhibitor
(Figure 5F). We conclude that Fzd2 is tyrosine phosphorylated
on Tyr552 by an as-yet-unidentified kinase, that this promotes
binding of Fzd2 to the SH2 domain of Fyn kinase, and that
this in turn activates Stat3 via phosphorylation of Tyr705. These
signal transduction events appear to involve the formation of a
multiprotein complex among Fzd2, Stat3, Fyn, and possibly
other proteins.852 Cell 159, 844–856, November 6, 2014 ª2014 Elsevier Inc.Fzd2 Knockdown or Treatment with an Anti-Fzd2
Antibody Reduces Tumor Growth and Metastasis
in a Mouse Xenograft
To assess the role played by Fzd2 in tumorigenesis, we used a
model in which FOCUS or Huh7 cells were injected subcutane-
ously into athymic mice. FOCUS cells grew rapidly in this xeno-
graft model, producing palpable tumors by day four. When the
tumors were 200 mm3 (as measured using a caliper), mice
were randomized into treatment and control groups. The former
received subcutaneous Fzd2-siRNA injections on alternate
days for 2 weeks, and the latter received transfection reagent
alone. We observed that tumor growth was significantly slower
in the treatment group compared to the control group, with a
noticeable lag in the exponential growth phase (Figure 6A).
Notably, tumor growth resumed when Fzd2-siRNA injections
were discontinued.
As a first step in developing a potential anti-Fzd2 therapeutic,
we generated and characterized Fzd2-specific neutralizing an-
tibodies in rats (Figures S6 and S7). We discovered an isotype-
specific epitope on Fzd2 (spanning residues Glu134-Leu163
in the cysteine rich and juxtamembrane domains) for which
cognate antibodies cause receptor internalization and inhibition
of downstream signaling (Figures S6 and S7). Targeting Fzd2
specifically with two different antibodies that recognize this
region reduced Stat3 transcription activity and tumor cell
migration and invasion in vitro (Figure S7). These antibodies
had no effect on Wnt3a-induced activation of TCF activity.
We tested the effects of monoclonal anti-Fzd2 antibodies that
cause Fzd2 internalization and degradation on tumor volume
and metastasis (Figure 6). Athymic mice were subcutaneously
injected with FOCUS-Luc cells and randomized into three
groups that received either vehicle control, a low antibody
dose (10 mg/kg Fzd2 mAb, q3d), or a high antibody dose
(30 mg/kg Fzd2 mAb, q3d). Injection of anti-Fzd2 antibody
caused a significant dose-dependent decrease in tumor
growth for two different antibodies (p < 0.05; Figure 6B). No
weight loss or other obvious adverse effects were observed.
When liver and lung tissue were recovered from mice treated
with one of the anti-Fzd2 antibodies, 1 of 12 mice was
observed to have metastases. In contrast, 12 of 16 control
mice had metastases to either liver or lung (Figure 6C). Consis-
tently, mice injected with Huh7 cells overexpressing Fzd2
showed no change in tumor growth but significantly higher inci-
dence of metastasis (nine of nine) than mice injected with
Huh7-vector-only-expressing cells (four of eight) (Figures 6C
and 6D). These data show that downregulating Fzd2 signaling
by antibody treatment attenuates Fzd2-mediated tumor growth
and metastasis, implying that Fzd2 may serve as a new drug
target for late stage HCC. Moreover, high expression of Fzd2
and/or Wnt5a/b may serve as a biomarker for potentially
responsive tumors.
Finally, we asked whether elevated expression of Wnt5, Fzd2,
and a set of 31 genes regulated by the Fzd2-Fyn-Stat3 pathway
(dubbed the ‘‘Fzd2 signature’’) could be used as a predictive
marker of metastasis and decreased overall survival in HCC
patients (Ye et al., 2003). This was accomplished using ADT
(alternating decision tree) analysis that generates trees in which
the contribution of each gene can be visualized. The Fzd2
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Figure 6. Fzd2 Knockdown or Treatment with an Anti-Fzd2 Antibody Reduces Tumor Growth and Metastasis in Mouse Xenograft
(A) Knockdown of Fzd2 expression reduces tumor growth in nude mice. FOCUS cells were injected s.c. into athymic mice and the ability of cells to form tumor
outgrowths was monitored in the presence (red shade) or absence (green shade) of siRNA against Fzd2.
(B) Treatment with two different clones of anti-Fzd2 antibodies reduced tumor growth in nude mice in a dose-dependent manner. Athymic mice were subcu-
taneously injected with FOCUS-Luc cells. When the outgrowths were 200 mm3, mice were divided at random into three groups (vehicle control, mAb-Fzd2
10 mg/kg, and mAb-Fzd2 30 mg/kg) for clone1 and into two groups (vehicle control and mAb-Fzd2 30 mg/kg) for clone 2 treatment. The treated group received
mAb-Fzd2 injection twice a week for 2 weeks, whereas the control group received s.c injection of vehicle.
(C) Ex vivo detection of metastasis after subcutaneous injection of FOCUS-luc or Huh7-Luc cells in nude mice. Liver and lungs were dissected frommice treated
with 30 mg/kg antibody clone 1 or 28 mg/kg antibody clone 2 as well as the vehicle-treated control group to examine metastasis. Liver and lungs were dissected
from mice injected with Huh7 cells expressing Fzd2 or vector only controls.
(D) Overexpression of Fzd2 expression in Huh7 cells does not affect tumor growth in nude mice. Huh7 cells transfected with either empty vector or vector
encoding Fzd2 gene were injected s.c. into athymic mice, and the ability of cells to form tumor outgrowths was monitored.
(E) A Fzd2-gene signature (55 genes), 3-gene signature (Fzd2, E-cadherin, and MMP9), and Fzd2-only correctly predicted metastasis in 46 cases of HCC. AUC
represent area under the curve.
(F) Kaplan-Meier survival curves for 46 HCC patients. The statistical p value was generated by the Cox-Mantel log-rank test.
Error bars indicate SEM. See also Figure S7 and Table S2.signature, or expression of Fzd2 alone, allowed us to predict
metastasis with 89% and 85% accuracy, respectively, in a
group of 46 HCC patients (Figure S7). Moreover, a signature
comprising three genes—Fzd2, CDH1, and MMP9—was as
accurate in predicting metastasis (89%) as the 55-gene signa-ture (Figures 6E and S7 and Table S2). HCC patients with tumors
that express high levels of Fzd2 had significantly poorer survival
(p < 0.0001) than patients with low Fzd2 expression (Figure 6F),
and Fzd2 expression was predictive of survival in a polynomial
model evaluated by cross-validation (Figure S7). We concludeCell 159, 844–856, November 6, 2014 ª2014 Elsevier Inc. 853
Figure 7. A Schematic of a Noncanonical Fzd2 Pathway
Wnt5-Fzd2-Fyn-Stat3 axis contributes to EMT program, cellular migration,
and tumor metastasis. Dashed line indicates the provisional nature of this
pathway.that high expression of Fzd2 is a potential marker of poor clinical
outcome in HCC patients.
DISCUSSION
Metastasis is responsible for as much as 90% of cancer-associ-
ated mortality (Weigelt et al., 2005). Regrettably, progress in
developing effective drugs specifically targeting metastasis or
cells with metastatic potential has been slow (Sleeman and
Steeg, 2010). Our study provides evidence that activation
of Fzd2-mediated signaling may be important in several meta-
static, late-stage cancers. We found that Fzd2 and its cognate
ligands Wnt5a and Wnt5b are overexpressed in metastatic can-
cer cell lines and tumors. This pattern of expression appears
to drive an autocrine loop that leads to expression of markers
of EMT and increased cell migration. Overall, our in vitro and
in vivo data suggest that Fzd2 is an oncogene and that overex-
pression of Fzd2 and signaling via a noncanonical Wnt pathway
contributes to the progression of late-stage metastatic cancers
(Figure 7).
Although there are numerous studies showing the migratory
potential of metastatic cells and relating metastasis to the
biology of the epithelial-mesenchymal transition, little is known
about how tumor cells access this fundamental cellular program.
In the case of Fzd2, we found that Wnt5 activation induces cell
migration via a noncanonical Wnt signaling pathway that in-
volves the tyrosine kinase Fyn and the transcription factor
Stat3. Stat3 is well known to mediate cytokine signaling and
to elicit a variety of inflammatory responses. Recently, RTK
or Oncostatin M-mediated activation of Stat3 was shown to
contribute to EMT through comprehensive alterations of tran-854 Cell 159, 844–856, November 6, 2014 ª2014 Elsevier Inc.scription factors such as Zeb1 (Balanis et al., 2013; Guo et al.,
2013). Our study, in multiple Wnt5-Fzd2-expressing tumor cells,
shows an unconventional mechanism of Stat3 activation that
drives EMT, cellular migration, and invasion.
The interaction of Fzd2 with Stat3 leads to Stat3 phosphoryla-
tion, but the mechanism of this activation is puzzling, as Fzd2 is
not known to be a kinase. We therefore looked for an intervening
kinase. We used a variety of systematic pathway mapping tools,
including panels of transcriptional reporters and protein arrays,
to identify the putative Stat3 kinase that lay downstream of
Fzd2. The most powerful approach was a newly developed sta-
tistical machine learning tool, KR, which can deconvolve the
polypharmacology of a panel of kinase inhibitors with complex
and overlapping selectivities against the raw phenotype of cell
migration. Combined with expression data in cell lines, the KR
approach identified the tyrosine kinase Fyn as the key mediator
of Fzd2-driven Stat3 phosphorylation. We then confirmed that
activated Fzd2 is tyrosine phosphorylated and that Fyn associ-
ates with Fzd2-Tyr552 through its SH2 domain. What still remains
unknown in this pathway is the kinase responsible for the initial
phosphorylation of Fzd2, which is required for mediating the
Fzd2-Fyn interaction. This activated complex can recruit and
phosphorylate Stat3 on Tyr705 and appears to drives a transcrip-
tional program that converts an epithelial morphology to amigra-
tory mesenchymal one. Perturbation of Fzd2 signaling also
affects the levels of other growth factors known to regulate
EMT, such as Tgfb2 and Bmp2, suggesting that this pathway
may be amaster regulator of EMT, a process important in cancer
and embryonic development. These studies make more con-
crete the general expectation that GPCRs and Src family kinases
are intimately involved in multilayered forms of crosstalk that
influence many cellular processes (Luttrell and Luttrell, 2004).
An understanding of this new noncanonical pathway down-
stream of Fzd2 may be important not only in the initiation of
metastasis but in chemoresistance. RTK-mediated signaling
pathways share multiple downstream signaling elements, and
inhibiting the dominant RTK often results in the compensatory
recruitment of downstream components by other RTKs, an
important mechanism of chemoresistance (Wilson et al., 2012).
Signaling through Fyn (or other Src family kinases) and Stat3 is
canonically activated by RTKs such as EGFR and c-Met. Our dis-
covery of Fzd2-mediated activation the Fyn-Stat3 axis may
represent a resistance mechanism by which cancer cells could
sustain proliferative signal independent of RTKs.
The gene signature regulated by the Wnt5/Fzd2 pathway
seems to have strong predictive value for metastasis and overall
patient survival; retrospective analysis of human tumors shows
that the survival of patients with HCC overexpressing Fzd2 is
substantially worse than for patients with tumors that exhibit
low Fzd2 expression. Many of the intracellular proteins (pStat3,
pSrc, pMek, and pErk) that are regulated by autocrine Wnt5-
Fzd2 signaling could also be used as potential pharmacody-
namic markers of drug response. The importance of extracel-
lular control of EMT through Fzd2 is enhanced by our discovery
of an isotype-specific epitope on Fzd2 for which we developed
an antibody that is able to mediate receptor internalization
and inhibition of downstream signaling. When we targeted
Fzd2 specifically with such an antibody, it reduced tumor cell
migration and invasion in vitro and inhibited tumor growth and
metastasis in mouse xenografts. However, whether the reduc-
tion in metastasis observed in the xenograft model is a conse-
quence of reduced dissemination, reduced survival in the
circulation, reduced extravasation, or prolonged dormancy re-
mains to be determined. Treatment with an anti-Fzd2 antibody
might therefore prove effective in the treatment of aggressive
HCC and other Wnt5/Fzd2-driven tumors. Furthermore, detailed
knowledge of a pathway that drives migration allows us to
consider codrugging strategies involving anti-Fzd2 antibodies
and existing small-molecule kinase inhibitors that target SFKs
(such as Dasatinib and Bosutinib). Our understanding of the
signaling cascade downstream of Fzd2 affords an opportunity
for the rational design of combination regimens based on anti-
Fzd2 therapy.
EXPERIMENTAL PROCEDURES
Cell Lines and Reagents
Cancer cell lines SNU449, SNU475, BT549, Hs578t, Calu-1, NCIH661, and
HepG2 cells were obtained from American Type Culture Collection (ATCC,
Rockville). FOCUS and Huh7 cells were obtained from J. Wands (Brown
University) and have been described previously (He et al., 1984). All cell lines
were maintained in Dulbecco’s modified Eagle medium (DMEM) supple-
mented with 10% (v/v) fetal bovine serum (FBS), 2 mM glutamine, 100 IU/ml
penicillin, and 100 mg/ml streptomycin.
Kinetic Wound-Healing Assay
The effect of Fzd2 knockdown on migration of FOCUS cells was studied using
a wound-healing assay. FOCUS cells were plated on 96-well plates (Essen
ImageLock, Essen Instruments), and a wound was scratched with wound
scratcher (Essen Instruments). Small-molecule inhibitors at different doses
were added immediately after wound scratching, and wound confluence
was monitored with Incucyte Live-Cell Imaging System and software (Essen
Instruments). Wound closure was observed every hr for 48–96 hr by comparing
the mean relative wound density of at least four biological replicates in each
experiment.
Tumorigenicity in Nude Mice
All in vivo experiments were performed using 6-week-old to 8-week-old
athymic nude mice. Mice were maintained in laminar flow rooms with constant
temperature and humidity. FOCUS cells were inoculated subcutaneously (s.c.)
into each flank of the mice. Cells (23 106 in suspension) were injected on day
0, and tumor growth was followed every 2 to 3 days by tumor diameter
measurements using vernier calipers. Tumor volumes (V) were calculated
using the formula: V = AB2/2 (A, axial diameter; B, rotational diameter). When
the outgrowths were200mm3, mice were divided at random into two groups
(control and treated). The treated group received Fzd2-siRNA injection or
anti-Fzd2 antibody on alternate days (MWF) for 2 weeks, whereas the control
group received s.c. injection of in vivo transfection reagent only or control IgG.
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